ProQR's CEO at #ASGCT2024 on NHP proof-of-concept data for the company's Axiomer RNA-editing platform

blonca9
May 9, 2024
1 min read

Daniel de Boer describes how Axiomer harnesses the body's natural ADAR editing process to turn an A into an I, he covers NHP data for cholestatic diseases presented at ASGCT, and highlights other potential use cases.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

ProQR's CEO at #ASGCT2024 on NHP proof-of-concept data for the company's Axiomer RNA-editing platform

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight